Biosimilar User Fee Act; Public Meeting; Correction

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2015-N-3326] AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. SUMMARY: The Food and Drug Administration is correcting a notice entitled “Biosimilar User Fee Act; Public Meeting” that appeared in the Federal Register of September 19, 2016 ( 81 FR 64171 ). The document announced a public meeting to discuss proposed recommendations for the reauthorization of the Biosimilar User Fee Act (BsUFA) for fiscal years (FYs) 2018 through 2022. The document was published with the incorrect date of the closure of the docket and incorrect transcript information. This document corrects those errors. FOR FURTHER INFORMATION CONTACT: Lisa Granger, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115, lisa.granger@fda.hhs.gov . SUPPLEMENTARY INFORMATION: In the Federal Register of Monday, September 19, 2016, in FR Doc. 2016-22442 , the following corrections are made: 1. On page 64172, in the first column, in the third sentence of the DATES section, “October 19, 2016” is corrected to read “October 28, 2016.” 2. On page 64175, in the third column, the section “ Transcripts: As soon as a transcript is available, FDA will post it at http://www.fda.gov/​ForIndustry/​UserFees/​BiosimilarUserFeeActBsUFA/​ucm461774.htm .” is corrected to read “ Transcripts…